Skip to content
Bending the Curve Trial by Trial
?

Platinum compoundsUsed in a few countriesDerivative of an earlier drugNeeds review

Miriplatin

Also known as SM-11355

A lipophilic platinum complex given into the hepatic artery in an iodised oil carrier for hepatocellular carcinoma. A 2026 review lists regional approval in Japan in 2009.

From discovery to approval

  1. c. 1986 · First described

    A 2009 paper says miriplatin (then SM-11355) is one of the lipophilic platinum complexes synthesised by Maeda and colleagues, citing their 1986 report. That report's abstract describes liposoluble 1,2-diaminocyclohexane platinum complexes used with lipiodol but does not name miriplatin.[2][1][3][4][5]

  2. No approval is recorded on this site.

How it works

A lipophilic platinum complex given into the hepatic artery in an oily carrier. It releases platinum compounds slowly; in a rat liver-tumour model it formed platinum-DNA adducts and caused extensive apoptosis (cell death).[1]

Where it came from and why

Later papers describe SM-11355 (miriplatin) as a platinum complex developed to treat hepatocellular carcinoma, given into the hepatic artery as a sustained-release suspension in iodised oil.

Cancers

Family and partners

Derived from: Cisplatin

Worth knowing

  • In a phase II trial in 16 chemotherapy-naive patients with hepatocellular carcinoma, 9 patients (56%; 95% CI 29.9-80.2%) achieved complete response by the study's definition.[6]
  • In a randomised phase II trial of 122 patients, the rate of the best therapeutic-effect category (TE V) was 26.5% with miriplatin and 17.9% with zinostatin stimalamer; hepatic vascular injury occurred in 0% versus 48.4%.[5]
  • A phase I study in 11 patients with hepatocellular carcinoma refractory to cisplatin/lipiodol did not reach the maximum allowable dose.[3]

References

  1. Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N, et al. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 2009;64(3):473-83. PubMedDOI
  2. Maeda M, Uchida NA, Sasaki T. Liposoluble platinum(II) complexes with antitumor activity. Jpn J Cancer Res. 1986;77(6):523-5. PubMed
  3. Fujiyama S, Shibata J, Maeda S, Tanaka M, Noumaru S, Sato K, et al. Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol. Br J Cancer. 2003;89(9):1614-9. PubMedDOI
  4. Kamusheva MS, Varbanov HP. Current clinical applications and future developments of platinum-based anticancer drugs. J Biol Inorg Chem. 2026;31(6):469-488. PubMedDOI
  5. Okusaka T, Kasugai H, Ishii H, Kudo M, Sata M, Tanaka K, et al. A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma. Invest New Drugs. 2012;30(5):2015-25. PubMedDOI
  6. Okusaka T, Okada S, Nakanishi T, Fujiyama S, Kubo Y. Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs. 2004;22(2):169-76. PubMedDOI